Community oncology’s growing role in the future of cancer care (Sponsored)
Community oncology is playing an increasingly important role in how cancer care is delivered across the United States, with a growing share of patients treated outside large academic medical centers. ...
9 Helmi 15min
The biggest potential drug launches of 2026
The leaders of this year’s list of the most anticipated drug launches will likely come as no surprise: Fierce’s annual report on the biggest potential launches of 2026 details how the next obesity med...
6 Helmi 13min
How Mirum is Advancing Rare Disease Care Through Strategic M&A (Sponsored)
Please see the following USPI, US ISI, EU SmPC and Canadian Product Monograph for complete LIVMARLI product information: US Important Safety Information (https://livmarli.com/important-safety-informat...
3 Helmi 14min
Why human expertise still matters in AI-driven med comms (Sponsored)
Artificial intelligence is reshaping medical communications, but it is not a substitute for human judgment. In this episode of The Top Line, experts from RTI Health Solutions explore how AI is being u...
2 Helmi 20min
Biopharma's rebound keeping pace so far
In this week’s episode of “The Top Line,” Fierce checks in with professional services juggernaut KPMG on the biopharma rebound many industry watchers predicted in the closing months of 2025. Fierce Ph...
30 Tammi 22min
JPM26: Sunshine, AI and the deals that weren't
With this year’s iteration of the J.P. Morgan Healthcare Conference in the rearview mirror, the biopharma industry has officially closed the door on 2025 as it heads into what is sure to be another ev...
23 Tammi 16min
From approval to value: Why evidence storytelling now matters (Sponsored)
As payers focus on long-term outcomes and real-world performance, value matters more than ever. RTI Health Solutions experts discuss how clear evidence storytelling drives access decisions.See omnystu...
19 Tammi 17min
Drug approvals went from crawl to sprint in 2025
In early 2025, the FDA was rocked by sweeping layoffs and leadership turnover, raising questions about whether the agency could maintain its pace in reviewing new drug applications. By the end of the ...
16 Tammi 13min
